Medical Disclaimer: This article is for general educational purposes only. Prostate health decisions, including screening and treatment, should always be made in consultation with a licensed healthcare provider based on your individual health history and risk factors.

The prostate — a walnut-sized gland sitting below the bladder — receives remarkably little attention from most men until problems arise. Yet prostate issues are among the most common health concerns for men over 50, and understanding the basics can make a meaningful difference in both outcomes and peace of mind.

Three distinct conditions affect the prostate in different ways: benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer. They're often conflated in public conversation, but they have different causes, different symptoms, and very different implications. This article focuses on what the science says about keeping the prostate healthy and navigating the evidence on screening and lifestyle.

Key Takeaways

  • Benign prostatic hyperplasia (BPH) — non-cancerous prostate enlargement — affects more than 50% of men by their 60s and over 80% by their 80s.
  • PSA screening for prostate cancer remains a nuanced decision that should be individualized — major medical organizations recommend shared decision-making with a physician, not blanket screening or blanket avoidance.
  • Diet, physical activity, and metabolic health have meaningful evidence-based associations with prostate health outcomes.
  • Many urinary symptoms attributed to prostate problems have other causes — always consult a physician for evaluation.

Benign Prostatic Hyperplasia (BPH): The Most Common Issue

BPH is the non-cancerous enlargement of the prostate gland. As the prostate grows, it can compress the urethra — the tube through which urine passes — causing a range of lower urinary tract symptoms (LUTS): frequent urination, urgency, weak stream, difficulty starting urination, and incomplete bladder emptying.

The prevalence of BPH increases dramatically with age. Autopsy studies have shown histological evidence of BPH in approximately 50% of men in their 50s, rising to more than 80% by the 9th decade of life.[1] However, having BPH tissue changes does not automatically mean experiencing significant symptoms — the relationship between prostate size and symptom severity is imperfect.

BPH is not cancer and does not increase cancer risk. The two conditions can coexist, but BPH itself is not a precancerous condition. Many men with significant BPH have no prostate cancer, and vice versa.

PSA Screening: Understanding the Evidence and the Debate

The prostate-specific antigen (PSA) blood test measures a protein produced by prostate cells. Elevated PSA can indicate prostate cancer — but also BPH, prostatitis, or even vigorous exercise before the test. This non-specificity is at the heart of the ongoing medical debate about screening.

Two large randomized trials — the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the U.S.-based Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial — reached different conclusions about mortality benefit from PSA screening, fueling over a decade of clinical controversy.[2,3]

The current U.S. Preventive Services Task Force (USPSTF) recommendation for men aged 55–69 is to engage in individualized decision-making — meaning that the decision to screen should be a conversation between patient and physician weighing personal values, family history, and risk factors. For men 70 and older, routine screening is generally not recommended given the risk-benefit profile.[4]

Lifestyle Factors and Prostate Health

Diet: The Mediterranean Pattern Shows Promise

Epidemiological research consistently shows lower rates of aggressive prostate cancer in Mediterranean populations. A systematic review published in Nutrients found that adherence to a Mediterranean dietary pattern — high in vegetables, legumes, fish, and olive oil, low in processed meats and refined sugars — was associated with reduced risk of prostate cancer incidence and progression.[5]

Lycopene — the carotenoid that gives tomatoes their red color — has been among the most studied compounds for prostate health, with several studies suggesting an association between lycopene intake and reduced prostate cancer risk, particularly for aggressive forms of the disease. However, evidence from randomized trials has been less consistent than observational data.[6]

Physical Activity and Metabolic Health

Obesity and metabolic syndrome are associated with increased risk of BPH symptoms and more aggressive prostate cancer. A meta-analysis published in European Urology found that higher body mass index (BMI) was significantly associated with increased risk of high-grade and advanced prostate cancer.[7]

Regular physical activity — particularly vigorous activity — has been associated with reduced risk of BPH-related urinary symptoms in prospective studies. The Health Professionals Follow-up Study found that men who exercised vigorously had significantly lower rates of BPH-related symptoms compared to sedentary men.[8]

Alcohol and Smoking

Heavy alcohol use and smoking are associated with worse prostate health outcomes across multiple conditions. Smoking in particular has been consistently linked to increased risk of dying from prostate cancer — even when controlling for disease stage at diagnosis — suggesting a direct biological relationship beyond detection bias.[9]

When to See a Doctor

Several symptoms warrant prompt evaluation by a physician — not watchful waiting or self-management:

  • Blood in urine or semen
  • Painful or burning urination
  • Inability to urinate (acute urinary retention — a medical emergency)
  • New lower back, hip, or pelvic pain in the context of other urinary symptoms
  • Sudden worsening of lower urinary tract symptoms

For men over 50 without symptoms, discussing prostate health — including whether PSA screening is appropriate for your individual situation — with a primary care provider or urologist is a reasonable, proactive step.

References

  1. Berry, S. J., et al. (1984). The development of human benign prostatic hyperplasia with age. Journal of Urology, 132(3), 474–479. doi.org/10.1016/s0022-5347(17)49698-4
  2. Schröder, F. H., et al. (2009). Screening and prostate-cancer mortality in a randomized European study. NEJM, 360(13), 1320–1328. doi.org/10.1056/NEJMoa0810084
  3. Andriole, G. L., et al. (2009). Mortality results from a randomized prostate-cancer screening trial. NEJM, 360(13), 1310–1319. doi.org/10.1056/NEJMoa0810696
  4. US Preventive Services Task Force. (2018). Screening for prostate cancer. JAMA, 319(18), 1901–1913. doi.org/10.1001/jama.2018.3710
  5. Ferro, M., et al. (2020). The Mediterranean diet as a genoprotective approach for prostate cancer risk reduction. Nutrients, 12(3), 826. doi.org/10.3390/nu12030826
  6. Giovannucci, E., et al. (2002). A prospective study of tomato products, lycopene, and prostate cancer risk. JNCI, 94(5), 391–398. doi.org/10.1093/jnci/94.5.391
  7. Gong, Z., et al. (2006). Obesity, diabetes, and risk of prostate cancer: results from the cancer prevention study II nutrition cohort. Cancer Epidemiology, Biomarkers & Prevention, 15(6), 1124–1131. doi.org/10.1158/1055-9965.EPI-05-0857
  8. Platz, E. A., et al. (1998). Physical activity and benign prostatic hyperplasia. Archives of Internal Medicine, 158(21), 2349–2356. doi.org/10.1001/archinte.158.21.2349
  9. Huncharek, M., et al. (2010). Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. American Journal of Public Health, 100(4), 693–701. doi.org/10.2105/AJPH.2008.150508